← Open Payments lookup

NPI 1013480979: Open Payments

NPI 1013480979. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,564 in 81 payments from 9 companies in 2025. Trend: 2023 $444 · 2024 $253 · 2025 $1,564

Food & beverage: $1,341Education: $223
CompanyPaymentsAmount
Teva Pharmaceuticals USA, Inc.15$410
Vanda Pharmaceuticals Inc.13$314
ABBVIE INC.14$180
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)10$168
Janssen Pharmaceuticals, Inc10$166
E.R. Squibb & Sons, L.L.C.10$139
Neurocrine BioSciences, Inc.5$113
Otsuka America Pharmaceutical, Inc.3$51
Axsome Therapeutics, Inc.1$24

Products named: FANAPT, VRAYLAR, CAPLYTA, COBENFY, AUSTEDO XR, INGREZZA, INVEGA SUSTENNA, HETLIOZ.